EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines

Congying Xia, Amanda M Smith, Bénédicte Lefebvre, Faizi A Jamal, Saro H Armenian, Daniel Koropeckyj-Cox, Liyong Zhang, Peter P Liu, Daniel Landsburg, Amy S Clark, Payal D Shah, Rebecca A Hubbard und 14 weitere

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2025.46201 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Congying Xia und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Anthracyclines, Natriuretic Peptide, Brain, Peptide Fragments, Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance There are gaps in the understanding of the clinical actionability of cardiovascular biomarkers for risk stratification during cardiotoxic chemotherapy.

Objectives

To gain insights into an N-terminal pro–B-type natriuretic peptide (NT-proBNP)–guided approach for cardioprotection in patients with breast cancer or lymphoma treated with anthracyclines and quantify the feasibility, tolerability, and exploratory efficacy of an NT-proBNP–guided strategy compared with usual care. Design, Setting, and Participants The NT-proBNP guide, a multicenter, randomized (stratified 1:1 by cancer type) clinical trial, included 100 participants with breast cancer or lymphoma initiating anthracyclines from March 18, 2021, to October 20, 2023, who were followed up for 12 months.

Interventions

Study participants in the NT-proBNP–guided arm had biomarker concentrations measured prior to anthracycline initiation (baseline), at each cycle, and at 3, 6, 9, and 12 months. An elevated NT-proBNP concentration triggered the initiation or titration of neurohormonal therapy. Participants in the usual care arm received routine care without prospective monitoring of NT-proBNP concentrations. Main Outcomes and Measures The primary outcomes were feasibility and safety of the NT-proBNP–guided approach. Feasibility was defined by recruitment, retention, and medication compliance rates. Safety outcomes were assessed according to the Common Terminology Criteria for Adverse Events, version 5.0, at each visit. Exploratory outcomes included differences in blinded, centrally quantified echocardiographic measures and NT-proBNP concentrations between the 2 arms. Analysis was performed on an intention-to-treat approach.

Results

Across 100 participants (mean [SD] age, 52.2 [14.4] years; 86 women [86.0%]), 74 (74.0%) had breast cancer and 26 (26.0%) had lymphoma. At 12 months, the retention rate was 92.7% (89 of 96). In the NT-proBNP–guided arm, 27 participants had NT-proBNP elevations, with a median time from baseline to first elevation of 14 days (IQR, 0-76 days), and a median time between the first NT-proBNP elevation and neurohormonal therapy prescription of 1 day (IQR, 0.5-9 days). There were no significant differences in targeted adverse events between the NT-proBNP–guided (23 events) and usual care (16 events) arms ( P = .13). At 3 months, left ventricular ejection fraction (LVEF) was modestly higher in the NT-proBNP–guided arm compared with usual care (mean difference, 2.0% [95% CI, 0.5%-3.5%]; P = .007). NT-proBNP concentrations increased in both arms over the study duration, but elevations were slightly attenuated in the NT-proBNP–guided arm. Conclusions and Relevance This randomized clinical trial of an NT-proBNP–guided approach to neurohormonal therapy in patients with cancer treated with anthracyclines demonstrates the feasibility, safety, and potential modest, early improvement in LVEF of a biomarker-guided approach. These findings provide support for further study of an NT-proBNP–guided approach to cardioprotection for patients undergoing cancer treatment. Trial Registration ClinicalTrials.gov Identifier: NCT04737265

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthracyclinesNatriuretic Peptide, BrainPeptide FragmentsBreast NeoplasmsLymphomaCardiotoxicityHumansFemaleMiddle AgedBiomarkersMaleAdultAgedFeasibility Studies

Substanzen

AnthracyclinesNatriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Peptide FragmentsBiomarkers

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Thalheimer Center for Cardio-Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, California.
  • University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia.
  • Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Xia, C., Smith, A. M., Lefebvre, B., Jamal, F. A., Armenian, S. H., Koropeckyj-Cox, D., Zhang, L., Liu, P. P., Landsburg, D., Clark, A. S., Shah, P. D., Hubbard, R. A., Huang, A., Golec, S., Hewitt, M., Wilcox, N. S., Chen, Z., Rethy, L., Jung, W., …, & Ky, B. (2025). Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.46201

Vancouver

Xia C, Smith AM, Lefebvre B, Jamal FA, Armenian SH, Koropeckyj-Cox D, et al. Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.46201

BibTeX
@article{Xia2025,
  author = {Xia, Congying and Smith, Amanda M and Lefebvre, Bénédicte and Jamal, Faizi A and Armenian, Saro H and Koropeckyj-Cox, Daniel and Zhang, Liyong and Liu, Peter P and Landsburg, Daniel and Clark, Amy S and Shah, Payal D and Hubbard, Rebecca A and Huang, Anran and Golec, Sophia and Hewitt, Maureen and Wilcox, Nicholas S and Chen, Zhen and Rethy, Leah and Jung, Wonyoung and Ko, Kyunga and Narayan, Vivek and Martei, Yehoda M and Lang, Ninian N and Januzzi, James L and Felker, G Michael and Ky, Bonnie},
  title = {Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2025.46201}
}
Kostenlos starten →